SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Vertex Pharmaceuticals (VRTX)
An SI Board Since August 1996
Posts SubjectMarks Bans Symbol
1169 64 0 VRTX
Emcee:  David Lieberman Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1069<i>I'm just not sure why anyone would buy the right to the $250M in miDewDiligence_on_SI-7/10/2009
1068I'm not sure there's anything surprising here. Vertex burn rate has alwarkrw-7/10/2009
1067VRTX Seeks to Monetize Telaprevir EU Milestones from JNJ: siliconinvestor.com DewDiligence_on_SI-7/10/2009
1066I think VX-770 cannot be much of a driver for the stock given focus is on telapridos15/28/2009
1065At the end of the day this can't be much of a driver for the stock given theBiomaven-5/27/2009
1064<b>Vertex Pharmaceuticals initiates Phase III registration program for VX-idos-5/27/2009
1063Re: Telaprevir rash (a/k/a/ “Fire in the Hole”) I’ve posted two quizzes relatinDewDiligence_on_SI-4/30/2009
1062Recognizing that the Telaprevir rash is a bona fide problem, VRTX introduced twoDewDiligence_on_SI-4/30/2009
1061The NEJM yesterday had two articles and an editorial on VRTX's drug. I havBiomaven-4/30/2009
1060VRTX’s goal for the HCV program: siliconinvestor.comDewDiligence_on_SI-4/25/2009
1059Telaprevir Data Presented at EASL Show Unprecedented SVR Rates in HCV Treatment-scaram(o)uche-4/25/2009
1058SGP recently denied the rumor that the FDA has restricted EPO use in the phase-3DewDiligence_on_SI14/23/2009
1057SGP results - note this was a treatment-naive population and note also the anemiBiomaven-4/23/2009
1056VCH-222 notes from today’s PR and CC: siliconinvestor.comDewDiligence_on_SI14/16/2009
1055Telaprevir PROVE-3 results made simple: siliconinvestor.comDewDiligence_on_SI-3/23/2009
1054EASL 2009 Poster Abstracts relevant to Telaprevir by non-Vertex people Abstractnsaf-3/23/2009
1053EASL 2009 Poster Abstract for VHC-916 Abstract 961 GENOTYPIC AND PHENOTYPIC ANtnsaf-3/23/2009
1052EASL 2009 Poster Abstracts for VHC-222 Abstract 935 IDENTIFICATION AND CHARACtnsaf-3/23/2009
1051Vertex Pharmaceuticals Closes on Acquisition of ViroChem Pharma -Purchase Pricetnsaf-3/13/2009
1050Vertex Pharmaceuticals Strengthens HCV Drug Development Portfolio, Adds Novel Potnsaf-3/4/2009
1049Out With Hedge Funds, In With Blue Bloods: Vertex Transforms Investor Base Via Ssim1-2/20/2009
1048Vertex Pharmaceuticals Announces Pricing of Common Stock Offering 10 million shatnsaf-2/19/2009
1047Thanks, Idit. p.s. I see that my reply to msg #1039 has been deleted, but mostDewDiligence_on_SI-2/11/2009
1046>Boger is 57 now and he’s made more than enough money for 50 lifetimes.< idos12/11/2009
1045Vertex expects wider 2009 loss and lower revenue Monday February 9, 7:18 pm ET Vtnsaf-2/9/2009
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News